Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
Launched by ASTRAZENECA · Oct 14, 2008
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female subjects must be of Non- child-bearing potential
- • Body mass index between 19 and 30 kg/m2 and weigh between 50-100 kg
- Exclusion Criteria:
- • Presence of any clinically significant illness
- • Abnormal vital signs
- • History of any conditions that may put the subject at risk by participating in the study
- • Participation in another clinical study.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alderley Park, , United Kingdom
Patients applied
Trial Officials
Raj Chetty, MD
Principal Investigator
AstraZeneca, Clinical Pharmacology Unit, Alderley Park
Mary Stuart, MD
Study Director
AstraZeneca,Parklands, Alderley Park
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials